Keenova Therapeutics layoffs, on the record
Every job cut, severance charge and restructuring Keenova Therapeutics reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 2,700 to approximately 1,600.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | approximately 2,700 | As of December 27, 2024 |
| 10-K for 2025 | approximately 1,600 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryThe company recorded severance costs as part of the costs of the Business Combination with Endo.
Word for word“During the year ended December 31, 2025, the Company recorded $141.2 million of costs, which includes legal, financial, other advisory and consulting costs, which primarily relate to shareholder matters, integration planning and execution, and regulatory matters associated with the Business Combination, as well as severance costs of approximately $44.1 million.” 10-K for 2025
Our summaryThe company recorded restructuring and related charges for termination benefits and contract termination costs tied to ceasing StrataGraft commercialization and development and winding down its production.
Word for word“During the year ended December 27, 2024, we incurred $10.5 million of restructuring and related charges, net, related to one-time termination benefits and contract termination costs for ceased commercialization and clinical development and wind down of production of StrataGraft.” 10-K for 2025
Our summaryThe company recognized income from a vendor refund tied to the StrataGraft production wind down, which reduced restructuring charges.
Word for word“During the year ended December 31, 2025, we recognized $2.2 million of income related to a vendor refund associated with the wind down of production of StrataGraft.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|
| 2016-09-30 | $32.7 million | — | — |
| 2017-12-29 | $31.2 million | — | — |
| 2018-12-28 | $103 million | — | — |
| 2019-12-27 | −$1.7 million | — | — |
| 2020-12-25 | $37.5 million | — | — |
| 2021-12-31 | $26.9 million | — | — |
| 2024-12-27 | $10.5 million | $10.5 million | $9.3 million |
| 2025-12-31 | $100,000 | −$2.2 million | — |
Keenova Therapeutics filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Keenova Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-04-15. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.